Literature DB >> 12402607

Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002.

Masaaki Nakayama1, Hiroyasu Yamamoto, Masato Ikeda, Toshio Hasegawa, Naohiko Kato, Hajime Takahashi, Yasushi Otsuka, Keitaro Yokoyama, Ryo Yamamoto, Yoshindo Kawaguchi, Tastuo Hosoya.   

Abstract

A growing incidence of encapsulating peritoneal sclerosis (EPS) has been reported recently in Japan, and it is now urgent to establish preventive measures against EPS development. In the present paper, we describe our observational results regarding the risk of EPS development and the characteristic features of patients with EPS, in terms of peritoneal morphology and peritoneal function as determined by peritoneal equilibration test. The ongoing working protocol for EPS prevention at Jikei University Hospital is also discussed. Our findings have revealed that long-term continuous ambulatory peritoneal dialysis (CAPD) is a risk factor for EPS development after transfer to hemodialysis from peritoneal dialysis (PD), and that, in most patients with EPS, peritoneal function is characterized by a longstanding high-transport state. The striking alterations in peritoneal morphology between patients with EPS and those with simple long-term CAPD hyperplasia include, in EPS patients, a prominent thickening of the collagenous layer of the peritoneum with neoangiogenesis and myofibroblastic transformation. Based on our findings, we established a withdrawal protocol for long-term CAPD patients, with the goal of preventing EPS. Those who have been on PD treatment for more than 72 months with high-transport state are candidates for withdrawal from PD, with performance of peritoneal lavage thereafter for a certain period of time. The clinical benefit of post-PD lavage has not yet been determined; however, the maneuver could be precluded in patients at low risk of EPS, because it was found that some patients can recover to average transport state during the period of PD withdrawal. Patients who remain high transporters with inflammatory reaction might require pharmacologic intervention, including prednisolone therapy. Further observations are required to validate our approach.

Entities:  

Mesh:

Year:  2002        PMID: 12402607

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  10 in total

1.  Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis.

Authors:  Yasushi Otsuka; Masaaki Nakayama; Masato Ikeda; Ali M Sherif; Keitaro Yokoyama; Hiroyasu Yamamoto; Yoshindo Kawaguchi
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 2.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

3.  Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model.

Authors:  Yoshimi Sekiguchi; Chieko Hamada; Yuuki Ro; Hirotaka Nakamoto; Masanori Inaba; Tetsutaro Shimaoka; Hiroaki Io; Ichiro Koyanagi; Seiki Aruga; Jiro Inuma; Kayo Kaneko; Yoko Hotta; Peter J Margetts; Hideki Mochizuki; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Artif Organs       Date:  2012-05-24       Impact factor: 1.731

4.  Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment.

Authors:  Ryo Yamamoto; Yasushi Otsuka; Masaaki Nakayama; Yukio Maruyama; Naohiko Katoh; Masato Ikeda; Hiroyasu Yamamoto; Keitaro Yokoyama; Yoshindo Kawaguchi; Masato Matsushima
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

5.  Effluent markers related to epithelial mesenchymal transition with adjusted values for effluent cancer antigen 125 in peritoneal dialysis patients.

Authors:  Sonoo Mizuiri; Hiromichi Hemmi; Michitsune Arita; Reibin Tai; Yoshinari Hattori; Atsuhiko Muto; Yasunori Suzuki; Yasushi Ohashi; Ken Sakai; Atsushi Aikawa
Journal:  Int J Nephrol       Date:  2011-07-06

6.  A case of CMV infection and encapsulating peritoneal sclerosis in a renal transplant recipient.

Authors:  Hyunchul Kim; Eunah Hwang; Sungbae Park; Hyungtae Kim; Seungyeup Han
Journal:  NDT Plus       Date:  2010-05-11

7.  Encapsulating Peritoneal Sclerosis in Long-Termed Peritoneal Dialysis Patients.

Authors:  Heng-Jung Hsu; Shih-Ying Yang; I-Wen Wu; Kuang-Hung Hsu; Chiao-Yin Sun; Chun-Yu Chen; Chin-Chan Lee
Journal:  Biomed Res Int       Date:  2018-11-13       Impact factor: 3.411

8.  A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity.

Authors:  Masaaki Nakayama; Chieko Hamada; Keitaro Yokoyama; Yudo Tanno; Nanae Matsuo; Junichiro Nakata; Yoshio Ishibashi; Atsushi Okuzawa; Kazuhiro Sakamoto; Tamaki Nara; Takatoshi Kakuta; Masaomi Nangaku; Takashi Yokoo; Yusuke Suzuki; Toshio Miyata
Journal:  Sci Rep       Date:  2020-10-16       Impact factor: 4.379

Review 9.  Risk factors for Encapsulating Peritoneal Sclerosis in patients undergoing peritoneal dialysis: A meta-analysis.

Authors:  Dashan Li; Yuanyuan Li; Hanxu Zeng; Yonggui Wu
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

10.  Clinical risk factors and outcomes of massive ascites accumulation after discontinuation of peritoneal dialysis.

Authors:  Ming-Shan Chang; Nai-Ching Chen; Chih-Yang Hsu; Chien-Wei Huang; Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang; Chien-Liang Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.